SH
SHC.US Sotera Health Co
- Market cap
- USD 4.58B
- P/E
- 26.8x
- P/B
- 6.34x
- ROE
- 25.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SHC.US undervalued?
Graham numberSHC.US trades 174.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sotera Health Co fundamental analysis
No fundamental analysis for Sotera Health Co yet.
Sotera Health Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sotera Health Co
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceuti…
Full company profileSotera Health Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sotera Health Co annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 1997 | 1998 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 746M | 778M | 818M | 931M | 1.00B | 1.05B | 1.10B | 1.16B | 1.24B |
| Gross Profit | - | - | 357M | 395M | 444M | 519M | 557M | 577M | 602M | 646M | 670M |
| Operating Income | - | - | 80.8M | 184M | 206M | 257M | 248M | 277M | 298M | 393M | 409M |
| EBITDA | - | - | 314M | 304M | 320M | 401M | -17.4M | 407M | 442M | 442M | 539M |
| Net Income | - | - | -5.87M | -20.9M | -38.6M | 117M | -234M | 51.4M | 44.4M | 77.9M | 185M |
| EPS | - | - | -0.02 | -0.07 | -0.14 | 0.42 | -0.83 | 0.18 | 0.16 | 0.27 | 0.64 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | 2.71B | 2.58B | 2.76B | 2.79B | 3.12B | 3.13B | 3.07B | 3.26B | 3.39B |
| Total Liabilities | - | - | 2.66B | 3.22B | 2.31B | 2.20B | 2.77B | 2.69B | 2.67B | 2.66B | 2.65B |
| Shareholders' Equity | - | - | 44.4M | -643M | 452M | 586M | 350M | 444M | 405M | 606M | 733M |
| Cash & Short-term Investments | - | - | 96.3M | 62.9M | 102M | 107M | 395M | 296M | 277M | 346M | 412M |
| Total Debt | - | - | 2.24B | 2.85B | 1.91B | 1.83B | 2.03B | 2.33B | 2.35B | 2.27B | 2.28B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 13.3M | 18.2M | 120M | 149M | 121M | 282M | 278M | -148M | 224M | 287M | 305M |
| Capital Expenditure | 0.00 | 22.6M | 72.6M | 57.3M | 53.5M | 102M | 182M | 215M | 179M | 138M | 194M |
| Free Cash Flow | - | - | 47.0M | 91.8M | 67.1M | 179M | 95.6M | -363M | 45.1M | 149M | 111M |
| Ratios | |||||||||||
| ROE | - | - | -13.2% | - | -8.5% | 19.9% | -66.7% | 11.6% | 11.0% | 12.9% | 25.2% |
| ROA | - | - | -0.2% | -0.8% | -1.4% | 4.2% | -7.5% | 1.6% | 1.4% | 2.4% | 5.5% |
| Net Profit Margin | - | - | -0.8% | -2.7% | -4.7% | 12.5% | -23.3% | 4.9% | 4.0% | 6.7% | 15.0% |
| Debt to Equity | - | - | 50.45x | - | 4.22x | 3.12x | 5.80x | 5.24x | 5.81x | 3.75x | 3.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sotera Health Co dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 150M | 0.53 | - |
| 2019 | USD 691M | 2.43 | - |
| 2018 | USD 176M | 0.71 | - |
| 1998 | USD 176M | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sotera Health Co
- Insiders 2.41%
- Institutions 97.59%
- Public & others 0.00%
- Shares outstanding 286M
- Free float 202M
Top funds holding SHC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 10.3M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 8.67M | 3.03% | +0.34% | Sep 2026 |
| Vanguard Small Cap Index | 6.10M | 2.13% | -2.22% | Sep 2026 |
| Janus Henderson Contrarian D | 5.57M | 1.95% | -4.77% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 3.40M | 1.19% | -5.07% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 3.10M | 1.08% | -0.57% | Sep 2026 |
| Fidelity Value | 3.04M | 1.06% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 2.11M | 0.74% | +8.79% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 1.75M | 0.61% | 0.00% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 1.72M | 0.60% | -0.26% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 1.67M | 0.59% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 1.55M | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.51M | 0.53% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.31M | 0.46% | +3.74% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 1.19M | 0.41% | -0.06% | Oct 2026 |
| DFA U.S. Small Cap I | 1.09M | 0.38% | 0.00% | Sep 2026 |
| Fidelity Mid Cap Index | 1.06M | 0.37% | -0.65% | Sep 2026 |
| JPMorgan Small Cap Equity A | 1.04M | 0.37% | -3.52% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 997K | 0.35% | +1.46% | Aug 2026 |
| MIG Core ETF | 989K | 0.35% | 0.00% | Oct 2026 |
Top institutions holding SHC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sessa Capital, L.P | 27.1M | 9.47% | +17.35% | Jun 2026 |
| Darsana Capital Partners LP | 27.0M | 9.45% | +3.85% | Jun 2026 |
| BlackRock Inc | 24.1M | 8.45% | +15.82% | Jun 2026 |
| OZ Management LLC | 24.0M | 8.40% | +10.51% | Jun 2026 |
| Sachem Head Capital Management LP | 15.6M | 5.45% | +33.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.2M | 4.26% | +13.37% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 11.9M | 4.18% | +12.61% | Jun 2026 |
| AQR Capital Management LLC | 10.7M | 3.76% | +59.72% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 10.5M | 3.68% | +15.26% | Jun 2026 |
| Jupiter Topco LLC | 8.40M | 2.94% | 0.00% | Jun 2026 |
| State Street Corp | 8.32M | 2.91% | +18.55% | Jun 2026 |
| FMR Inc | 6.17M | 2.16% | +21,490.32% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 5.97M | 2.09% | +2.90% | Sep 2026 |
| Voss Capital LLC | 5.83M | 2.04% | +19.58% | Jun 2026 |
| Geode Capital Management, LLC | 5.22M | 1.83% | +12.50% | Jun 2026 |
| Irenic Capital Management LP | 5.14M | 1.80% | +17.95% | Jun 2026 |
| Lakewood Capital Management, LP | 3.98M | 1.39% | -3.05% | Jun 2026 |
| NORGES BANK | 3.51M | 1.23% | +36.84% | Jun 2026 |
| ION Fund Management Ltd | 3.34M | 1.17% | +180.18% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.08M | 1.08% | +49.11% | Jun 2026 |
Sotera Health Co company profile
- Company name
- Sotera Health Co
- Ticker
- SHC.US
- Exchange
- USA Stocks
- Listed since
- Nov 20, 2020
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 9100 South Hills Blvd, Broadview Heights, OH, United States, 44147
- Phone
- 440 262 1410
- Website
- soterahealth.com
About Sotera Health Co
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Sotera Health Co management
10- Mr. Michael B. Petras Jr.Executive Chairman of the Board · born 1969
- Mr. Jonathan M. LyonsSenior VP & CFO · born 1978
- Mr. Michael P. RutzPresident of Sterigenics U.S., LLC · born 1971
- Mr. Alton E. ShaderCEO & Director · born 1973
- Mr. Robert G. HauzieChief Information Officer
- Ms. Erika OstrowskiSenior VP, General Counsel & Corporate Secretary
- Ms. Kristin A. GibbsChief Marketing Officer
- Mr. William O. Lehmann Jr., J.D., M.B.A.Senior Vice President of Strategy & Corporate Development · born 1966
- Ms. Sally R. TurnerChief Human Resources Officer
- Ms. Danielle J. MentureSenior Vice President of Global Environmental, Health & Safety and Sustainability